IBDEI0JR ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9611,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9611,1,4,0)
 ;;=4^196.3
 ;;^UTILITY(U,$J,358.3,9611,1,5,0)
 ;;=5^Mets to Lymph Nodes,Axillary Or Brachial
 ;;^UTILITY(U,$J,358.3,9611,2)
 ;;=^267317
 ;;^UTILITY(U,$J,358.3,9612,0)
 ;;=196.0^^58^635^73
 ;;^UTILITY(U,$J,358.3,9612,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9612,1,4,0)
 ;;=4^196.0
 ;;^UTILITY(U,$J,358.3,9612,1,5,0)
 ;;=5^Mets to Lymph Nodes,Cervical
 ;;^UTILITY(U,$J,358.3,9612,2)
 ;;=Lymph Nodes^267314
 ;;^UTILITY(U,$J,358.3,9613,0)
 ;;=196.1^^58^635^74
 ;;^UTILITY(U,$J,358.3,9613,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9613,1,4,0)
 ;;=4^196.1
 ;;^UTILITY(U,$J,358.3,9613,1,5,0)
 ;;=5^Mets to Lymph Nodes,Mediastinal 
 ;;^UTILITY(U,$J,358.3,9613,2)
 ;;=Lymph Nodes^267315
 ;;^UTILITY(U,$J,358.3,9614,0)
 ;;=196.8^^58^635^75
 ;;^UTILITY(U,$J,358.3,9614,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9614,1,4,0)
 ;;=4^196.8
 ;;^UTILITY(U,$J,358.3,9614,1,5,0)
 ;;=5^Mets to Lymph Nodes,Multiple Sites
 ;;^UTILITY(U,$J,358.3,9614,2)
 ;;=^267320
 ;;^UTILITY(U,$J,358.3,9615,0)
 ;;=V10.51^^58^635^33
 ;;^UTILITY(U,$J,358.3,9615,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9615,1,4,0)
 ;;=4^V10.51
 ;;^UTILITY(U,$J,358.3,9615,1,5,0)
 ;;=5^H/O Bladder Cancer
 ;;^UTILITY(U,$J,358.3,9615,2)
 ;;=^295228
 ;;^UTILITY(U,$J,358.3,9616,0)
 ;;=V10.3^^58^635^34
 ;;^UTILITY(U,$J,358.3,9616,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9616,1,4,0)
 ;;=4^V10.3
 ;;^UTILITY(U,$J,358.3,9616,1,5,0)
 ;;=5^H/O Breast Cancer
 ;;^UTILITY(U,$J,358.3,9616,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,9617,0)
 ;;=V10.41^^58^635^35
 ;;^UTILITY(U,$J,358.3,9617,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9617,1,4,0)
 ;;=4^V10.41
 ;;^UTILITY(U,$J,358.3,9617,1,5,0)
 ;;=5^H/O Cervical Cancer
 ;;^UTILITY(U,$J,358.3,9617,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,9618,0)
 ;;=V10.05^^58^635^36
 ;;^UTILITY(U,$J,358.3,9618,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9618,1,4,0)
 ;;=4^V10.05
 ;;^UTILITY(U,$J,358.3,9618,1,5,0)
 ;;=5^H/O Colon Cancer
 ;;^UTILITY(U,$J,358.3,9618,2)
 ;;=H/O Colon Cancer^295207
 ;;^UTILITY(U,$J,358.3,9619,0)
 ;;=V10.03^^58^635^37
 ;;^UTILITY(U,$J,358.3,9619,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9619,1,4,0)
 ;;=4^V10.03
 ;;^UTILITY(U,$J,358.3,9619,1,5,0)
 ;;=5^H/O Esophageal Cancer
 ;;^UTILITY(U,$J,358.3,9619,2)
 ;;=^295205
 ;;^UTILITY(U,$J,358.3,9620,0)
 ;;=V10.60^^58^635^39
 ;;^UTILITY(U,$J,358.3,9620,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9620,1,4,0)
 ;;=4^V10.60
 ;;^UTILITY(U,$J,358.3,9620,1,5,0)
 ;;=5^H/O Leukemia
 ;;^UTILITY(U,$J,358.3,9620,2)
 ;;=H/O Leukemia^295231
 ;;^UTILITY(U,$J,358.3,9621,0)
 ;;=V10.11^^58^635^40
 ;;^UTILITY(U,$J,358.3,9621,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9621,1,4,0)
 ;;=4^V10.11
 ;;^UTILITY(U,$J,358.3,9621,1,5,0)
 ;;=5^H/O Lung Cancer
 ;;^UTILITY(U,$J,358.3,9621,2)
 ;;=H/O Lung Cancer^295211
 ;;^UTILITY(U,$J,358.3,9622,0)
 ;;=V10.79^^58^635^41
 ;;^UTILITY(U,$J,358.3,9622,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9622,1,4,0)
 ;;=4^V10.79
 ;;^UTILITY(U,$J,358.3,9622,1,5,0)
 ;;=5^H/O Lymphoma
 ;;^UTILITY(U,$J,358.3,9622,2)
 ;;=H/O Lymphoma^295238
 ;;^UTILITY(U,$J,358.3,9623,0)
 ;;=V10.82^^58^635^43
 ;;^UTILITY(U,$J,358.3,9623,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9623,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,9623,1,5,0)
 ;;=5^H/O Malig Melanoma Of Skin
 ;;^UTILITY(U,$J,358.3,9623,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,9624,0)
 ;;=V10.02^^58^635^45
 ;;^UTILITY(U,$J,358.3,9624,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9624,1,4,0)
 ;;=4^V10.02
 ;;^UTILITY(U,$J,358.3,9624,1,5,0)
 ;;=5^H/O Oral Cavity/Pharynx Cancer
